[go: up one dir, main page]

NO20075412L - Fremgangsmater og preparater til modulering av hyperstabilisert C-MET - Google Patents

Fremgangsmater og preparater til modulering av hyperstabilisert C-MET

Info

Publication number
NO20075412L
NO20075412L NO20075412A NO20075412A NO20075412L NO 20075412 L NO20075412 L NO 20075412L NO 20075412 A NO20075412 A NO 20075412A NO 20075412 A NO20075412 A NO 20075412A NO 20075412 L NO20075412 L NO 20075412L
Authority
NO
Norway
Prior art keywords
met
hyper
modulating
stabilized
preparations
Prior art date
Application number
NO20075412A
Other languages
English (en)
Inventor
Monica Kong-Beltran
Dineli M Wickramasinghe
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37053941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20075412(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20075412L publication Critical patent/NO20075412L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Samrnendrag Oppfinnelsen tilveiebringer fremgangsmåter og preparater for å modulere HGF/c-metsignaleringsveien, spesielt ved å inhibere et hyperstabilisert c-met-protein.
NO20075412A 2005-03-25 2007-10-24 Fremgangsmater og preparater til modulering av hyperstabilisert C-MET NO20075412L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66548205P 2005-03-25 2005-03-25
PCT/US2006/010850 WO2006104911A2 (en) 2005-03-25 2006-03-24 Methods and compositions for modulating hyperstabilized c-met

Publications (1)

Publication Number Publication Date
NO20075412L true NO20075412L (no) 2007-12-21

Family

ID=37053941

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075412A NO20075412L (no) 2005-03-25 2007-10-24 Fremgangsmater og preparater til modulering av hyperstabilisert C-MET

Country Status (17)

Country Link
US (2) US7615529B2 (no)
EP (1) EP1868648B1 (no)
JP (2) JP2008535821A (no)
KR (1) KR20080000613A (no)
CN (1) CN101184506B (no)
AU (1) AU2006229989B2 (no)
BR (1) BRPI0611468A2 (no)
CA (1) CA2599988A1 (no)
ES (1) ES2539790T3 (no)
IL (1) IL185708A (no)
MX (1) MX2007011652A (no)
NO (1) NO20075412L (no)
NZ (1) NZ561211A (no)
RU (1) RU2404193C2 (no)
SG (1) SG159547A1 (no)
WO (1) WO2006104911A2 (no)
ZA (1) ZA200707953B (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2404193C2 (ru) 2005-03-25 2010-11-20 Дженентек, Инк. Способ лечения опухоли у субъекта
CN102014913A (zh) * 2008-03-06 2011-04-13 健泰科生物技术公司 C-met和egfr拮抗剂的联合疗法
RU2547600C2 (ru) * 2008-10-01 2015-04-10 Эмджен Рисерч (Мьюник) Гмбх Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
WO2010115553A1 (en) * 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-2/anti-c-met antibodies
PE20120550A1 (es) 2009-04-07 2012-05-21 Roche Glycart Ag ANTICUERPOS BIESPECIFICOS ANTI-ErbB-3/ANTI-C-MET
EP2421898B1 (en) 2009-04-20 2016-03-16 Oxford BioTherapeutics Ltd Antibodies specific to cadherin-17
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
WO2011057120A1 (en) * 2009-11-05 2011-05-12 Genentech, Inc. Methods and composition for secretion of heterologous polypeptides
US9068011B2 (en) 2010-03-10 2015-06-30 Genmab A+S Monoclonal antibodies against c-Met
SG189835A1 (en) * 2010-10-20 2013-06-28 Oxford Biotherapeutics Ltd Antibodies
RU2013155695A (ru) 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
WO2013033008A2 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
JP2014530201A (ja) 2011-09-20 2014-11-17 イーライ リリー アンド カンパニー 抗ｃ−Ｍｅｔ抗体
WO2013049112A1 (en) * 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
WO2013078170A1 (en) * 2011-11-21 2013-05-30 Genentech, Inc. Purification of anti-c-met antibodies
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
ES2530968T3 (es) 2012-10-12 2015-03-09 Spirogen Sarl Pirrolobenzodiazepinas y conjugados de las mismas
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
AU2014225661A1 (en) 2013-03-06 2015-09-10 Merrimack Pharmaceuticals, Inc. Anti-c-Met tandem Fc bispecific antibodies
WO2014140174A1 (en) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
MX2016011637A (es) 2014-03-14 2017-04-13 Genentech Inc Metodos y composiciones para secrecion de polipeptidos heterologos.
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
CA2961323C (en) 2014-09-16 2021-11-30 Symphogen A/S Anti-met antibodies and compositions
GB201419108D0 (en) * 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
EP3270918A4 (en) 2015-03-16 2018-10-24 Celldex Therapeutics, Inc. Anti-met antibodies and methods of use thereof
DK3512547T3 (en) 2016-09-14 2020-12-07 Abbvie Biotherapeutics Inc Anti-pd-1-antistoffer
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
BR112020020961A2 (pt) 2018-04-17 2021-01-19 Endocyte, Inc. Métodos de tratamento de câncer
CN113286616A (zh) 2018-05-23 2021-08-20 Adc治疗有限公司 分子佐剂
CA3106403A1 (en) 2018-07-15 2020-01-23 Enochian BioPharma, Inc. Methods and compositions using recombinant dendritic cells for cancer therapy
PH12021552030A1 (en) 2019-02-26 2022-08-15 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
MX2022002886A (es) 2019-09-16 2022-04-06 Regeneron Pharma Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet.
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
CN114478788B (zh) 2020-11-11 2025-07-18 北京免疫方舟医药科技有限公司 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
AU2438997A (en) 1996-04-05 1997-10-29 Thomas Jefferson University Methods for the diagnosis and prognosis of cancer
EP0922102B1 (en) 1996-07-03 2010-04-21 Genentech, Inc. Hepatocyte growth factor receptor agonists and uses thereof
DE19651443A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
CA2481507A1 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004072117A2 (en) * 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
EP1636593B9 (en) * 2003-06-06 2009-12-16 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US20050233960A1 (en) * 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
US20050227324A1 (en) * 2003-12-19 2005-10-13 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
RU2007139516A (ru) 2005-03-25 2009-04-27 Дженентек, Инк. (Us) Мутации с-мет при раке легких
RU2404193C2 (ru) 2005-03-25 2010-11-20 Дженентек, Инк. Способ лечения опухоли у субъекта

Also Published As

Publication number Publication date
US8536118B2 (en) 2013-09-17
JP2012232979A (ja) 2012-11-29
RU2404193C2 (ru) 2010-11-20
AU2006229989A1 (en) 2006-10-05
RU2007139452A (ru) 2009-04-27
ZA200707953B (en) 2009-06-24
EP1868648A2 (en) 2007-12-26
CN101184506B (zh) 2013-07-17
WO2006104911A3 (en) 2007-02-22
IL185708A0 (en) 2008-01-06
CN101184506A (zh) 2008-05-21
IL185708A (en) 2014-11-30
AU2006229989B2 (en) 2012-02-02
WO2006104911A2 (en) 2006-10-05
NZ561211A (en) 2011-03-31
US7615529B2 (en) 2009-11-10
MX2007011652A (es) 2007-11-14
KR20080000613A (ko) 2008-01-02
CA2599988A1 (en) 2006-10-05
US20100028337A1 (en) 2010-02-04
HK1109075A1 (en) 2008-05-30
ES2539790T3 (es) 2015-07-06
EP1868648B1 (en) 2015-04-15
JP2008535821A (ja) 2008-09-04
US20060270594A1 (en) 2006-11-30
SG159547A1 (en) 2010-03-30
BRPI0611468A2 (pt) 2010-09-08

Similar Documents

Publication Publication Date Title
NO20075412L (no) Fremgangsmater og preparater til modulering av hyperstabilisert C-MET
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
NO20075693L (no) Modulerende forbindelser av indolamin-2,3-dioksygenase og fremgangsmater for anvendelse av samme
NO20081160L (no) Benzimidazoltiofen forbindelser
EA200701918A1 (ru) Белок липокалин
DK1636593T3 (da) Modulering af vekselvirkningen mellem HGF-beta-kæde og c-met
WO2008033408A3 (en) Methods for identifying compounds that modulate cell signaling and methods employing such compounds
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
NO20075647L (no) Kjemiske forbindelser
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
MEP35408A (en) Tweak binding antibodies
DK1592786T3 (da) Diagnosticering og behandling af multipel sulfatase-defekt og andet ved anvendelse af et formylglycin-dannende enzym (FGE).
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
CR9637A (es) Proteinas de enlace il-6
DK1836169T5 (da) Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
CR9223A (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen
MX2009007911A (es) Inhibidores de proteina tirosina fosfatasa 1b aromaticos fusionados.
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
MY145788A (en) Antitumoral dihydropyran-2-one compounds
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application